GI
TRVI icon

GAMMA Investing’s Trevi Therapeutics TRVI Stock Holding History

GAMMA Investing’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.85K Buy
99
+5
+5% +$73 ﹤0.01% 3745
2026
Q1 		$1.12K Sell
94
-86
-48% -$963 ﹤0.01% 3811
2025
Q4 		$2.25K Buy
180
+111
+161% +$1.28K ﹤0.01% 3563
2025
Q3 		$631 Sell
69
-25
-27% -$187 ﹤0.01% 3688
2025
Q2 		$514 Sell
94
-53
-36% -$330 ﹤0.01% 3632
2025
Q1 		$925 Buy
+147
New +$701 ﹤0.01% 3571

Other funds holding TRVI

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

GAMMA Investing's TRVI Position: Q2 2026 in Review

GAMMA Investing increased its Trevi Therapeutics (TRVI) stake by 5.3% in Q2 2026, buying an estimated $73 and bringing the position to 99 shares worth $1.85K. The position accounts for ﹤0.01% of the portfolio, ranked #3745.

GAMMA Investing first reported a position in TRVI in Q1 2025 and has held it in 6 quarters since. The position peaked at $2.25K in Q4 2025. 217 funds tracked by Wall St. Rank hold TRVI as of Q2 2026.

  • GAMMA Investing held 99 shares of Trevi Therapeutics worth $1.85K as of Q2 2026.
  • GAMMA Investing bought 5 Trevi Therapeutics shares in Q2 2026, an estimated $73.
  • Trevi Therapeutics made up ﹤0.01% of GAMMA Investing's portfolio in Q2 2026, its #3745 holding.
  • GAMMA Investing first reported a position in Trevi Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • GAMMA Investing's Trevi Therapeutics position peaked at $2.25K in Q4 2025.
  • 217 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q2 2026.

Based on GAMMA Investing's 13F filing for Q2 2026, filed 7 Jul 2026.